A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age

Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Langley, Joanne, Pastural, Elodie, Halperin, Scott, McNeil, Shelly, ElSherif, May, MacKinnon-Cameron, Donna, Ye, Lingyun, Grange, Cécile, Thibodeau, Valérie, Cailhier, Jean-François, Lapointe, Rejean, McElhaney, Janet, Martin, Luis, Bolduc, Marilène, Laliberté-Gagné, Marie-Eve, Leclerc, Denis, Savard, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564144/
https://www.ncbi.nlm.nih.gov/pubmed/32698532
http://dx.doi.org/10.3390/vaccines8030393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564144/
https://www.ncbi.nlm.nih.gov/pubmed/32698532
http://dx.doi.org/10.3390/vaccines8030393

Ejemplares similares